logo
logo

Remix Therapeutics Closes $60 Million Financing To Advance Rem-422, Pipeline Of Small Molecule Therapies Designed To Reprogram Rna Processing To Treat Disease

Jan 03, 2024over 1 year ago

Amount Raised

$60 Million

WatertownBiotechnology

Investors

Willett AdvisorsWtt InvestmentSurveyorCasdin CapitalArch Venture PartnersAlexandria Venture InvestmentsForesite CapitalAtlas VentureThe Column Group

Description

Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, today announced the close of a $60 million financing led by The Column Group. The financing includes participation from existing investors Atlas Venture, Foresite Capital, Alexandria Venture Investments, Arch Venture Partners, Casdin Capital, and Surveyor (a Citadel company) along with new investors WTT Investment, Willett Advisors, and others. The funds will support clinical development of the company's lead program, REM-422, and further advancement of a pipeline of RNA processing targeted therapeutics.

Company Information

Company

Remix Therapeutics

Location

Watertown, South Dakota, United States

About

Remix launched in 2020 with a vision to transform patient's lives through modulation of RNA processing. Our breakthrough science provides a path to identify small molecules that impact the expression of disease driving mRNAs and proteins. We take on the challenge of addressing drug targets in diseases of high unmet medical need to bring new therapeutic options to patients. Remix has a commitment to demonstrate the highest levels of scientific integrity with urgency because those patients are counting on us to deliver. With an in-house technology platform built from scratch, we have rapidly generated multiple drug discovery programs that are advancing towards the clinic.

Funding Insights

Based on industry data
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Related People